Mucoflav (Carbocisteine)

Carbocisteine reduces the viscosity of mucus by breaking disulfide bonds within mucopolysaccharide chains. This chemical modification makes secretions less sticky and easier for ciliary action and cough mechanisms to transport out of the airways, thereby improving ventilation and reducing cough frequency.

The specific dose of Mucoflav is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of the condition, and renal function. Dosage regimens can vary, and the prescriber will provide individualized instructions that should be followed precisely.

Safety data for carbocisteine during pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing Mucoflav to pregnant or nursing women. Consultation with a physician is essential to make an informed decision.

To place an order, submit an enquiry on the Mucoflav product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mucoflav (carbocisteine) differs from agents like N‑acetylcysteine in its mechanism; carbocisteine primarily reduces mucus viscosity by breaking disulfide bonds, whereas N‑acetylcysteine also provides antioxidant effects. Clinical choice often depends on patient tolerance, specific respiratory condition, and physician preference, as both classes aim to improve mucus clearance.

Mucoflav should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid environments such as bathrooms.

Mucoflav is taken orally, usually with a glass of water. It can be administered with or without food, but taking it with meals may reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome, significant liver enzyme elevations, neutropenia, hematuria, and gastrointestinal bleeding. Any signs of these conditions require immediate medical evaluation and discontinuation of the drug.

Mucoflav should be avoided in individuals with known hypersensitivity to carbocisteine or any excipients in the formulation. Patients with severe renal impairment may require dose adjustment, and those with uncontrolled asthma should be monitored closely. Consultation with a healthcare provider is essential before initiating therapy.